Effect of carrier type and surfactant concentration on the silymarin release

Valentyn Mohylyuk; Thomas Pauly; Oleksandr Dobrovolnyi; Nathan Scott; David Jones; Gavin Andrews

Effect of carrier type and surfactant concentration on the silymarin release

Valentyn Mohylyuk, Thomas Pauly, Oleksandr Dobrovolnyi, Nathan Scott, David Jones, Gavin Andrews

School of Pharmacy

Research output: Contribution to conference › Poster › peer-review

72 Downloads (Pure)

Abstract

Silymarin, being the flavonoid complex isolated from Silybum marianum fruits is widely used and has new prospects to be used in medicine. Silybin (also known as silibinin) is main component of silymarin with attributed therapeutically properties. Silymarin behave as weak acid, can be considered as a Class II drug and has slow dissolution kinetics at pH 7.4 and low bioavailability (1). The inhibition of gut wall efflux with additional formulation components, the bypassing the gut wall efflux by lymphatic transport and the increasing intestinal flux by increasing of drug concentration in the place of absorption are well-known strategies for the improvement of bioavailability. The main objective of this study was to justify the chosen formulation strategy and to investigate the drug release of silymarin as function of carrier type (Avicel® PH-102 vs. Syloid® XDP 3150) and surface-active substance (Tween® 80) concentration.

Original language	English
Publication status	Published - 11 May 2021
Event	12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology - Vienna, Austria Duration: 11 May 2021 → 14 May 2021

Conference

Conference	12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
Country/Territory	Austria
City	Vienna
Period	11/05/2021 → 14/05/2021

Access to Document

Effect of carrier type and surfactant concentration on the silymarin release
© 2020 The Authors & QUB.
Other version, 473 KB

Cite this

@conference{83741b4f67694c309a106b838ddc92ad,

title = "Effect of carrier type and surfactant concentration on the silymarin release",

abstract = "Silymarin, being the flavonoid complex isolated from Silybum marianum fruits is widely used and has new prospects to be used in medicine. Silybin (also known as silibinin) is main component of silymarin with attributed therapeutically properties. Silymarin behave as weak acid, can be considered as a Class II drug and has slow dissolution kinetics at pH 7.4 and low bioavailability (1). The inhibition of gut wall efflux with additional formulation components, the bypassing the gut wall efflux by lymphatic transport and the increasing intestinal flux by increasing of drug concentration in the place of absorption are well-known strategies for the improvement of bioavailability. The main objective of this study was to justify the chosen formulation strategy and to investigate the drug release of silymarin as function of carrier type (Avicel{\textregistered} PH-102 vs. Syloid{\textregistered} XDP 3150) and surface-active substance (Tween{\textregistered} 80) concentration.",

author = "Valentyn Mohylyuk and Thomas Pauly and Oleksandr Dobrovolnyi and Nathan Scott and David Jones and Gavin Andrews",

year = "2021",

month = may,

day = "11",

language = "English",

note = "12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology ; Conference date: 11-05-2021 Through 14-05-2021",

}

TY - CONF

T1 - Effect of carrier type and surfactant concentration on the silymarin release

AU - Mohylyuk, Valentyn

AU - Pauly, Thomas

AU - Dobrovolnyi, Oleksandr

AU - Scott, Nathan

AU - Jones, David

AU - Andrews, Gavin

PY - 2021/5/11

Y1 - 2021/5/11

N2 - Silymarin, being the flavonoid complex isolated from Silybum marianum fruits is widely used and has new prospects to be used in medicine. Silybin (also known as silibinin) is main component of silymarin with attributed therapeutically properties. Silymarin behave as weak acid, can be considered as a Class II drug and has slow dissolution kinetics at pH 7.4 and low bioavailability (1). The inhibition of gut wall efflux with additional formulation components, the bypassing the gut wall efflux by lymphatic transport and the increasing intestinal flux by increasing of drug concentration in the place of absorption are well-known strategies for the improvement of bioavailability. The main objective of this study was to justify the chosen formulation strategy and to investigate the drug release of silymarin as function of carrier type (Avicel® PH-102 vs. Syloid® XDP 3150) and surface-active substance (Tween® 80) concentration.

AB - Silymarin, being the flavonoid complex isolated from Silybum marianum fruits is widely used and has new prospects to be used in medicine. Silybin (also known as silibinin) is main component of silymarin with attributed therapeutically properties. Silymarin behave as weak acid, can be considered as a Class II drug and has slow dissolution kinetics at pH 7.4 and low bioavailability (1). The inhibition of gut wall efflux with additional formulation components, the bypassing the gut wall efflux by lymphatic transport and the increasing intestinal flux by increasing of drug concentration in the place of absorption are well-known strategies for the improvement of bioavailability. The main objective of this study was to justify the chosen formulation strategy and to investigate the drug release of silymarin as function of carrier type (Avicel® PH-102 vs. Syloid® XDP 3150) and surface-active substance (Tween® 80) concentration.

M3 - Poster

T2 - 12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

Y2 - 11 May 2021 through 14 May 2021

ER -

Effect of carrier type and surfactant concentration on the silymarin release

Abstract

Conference

Access to Document

Fingerprint

Cite this